Lupin Inks Deal With Cornerstone

Lupin Ltd. has signed a development and licensing agreement for an anti-infective drug with Cornerstone BioPharma Inc., the Bombay Stock Exchange said. It said Lupin will receive a total of $10.5 million from Cornerstone, partly linked to milestones reached in the development of the drug. Both companies will be involved in the development of the drug and Cornerstone will have the rights to sell the drug in the United States once regulatory approval was received, it said.

The Economic Times (http://economictimes.indiatimes.com/articleshow/1099268.cms)